92 124

Cited 1 times in

Development of a radionuclide-labeled monoclonal anti-CD55 antibody with theranostic potential in pleural metastatic lung cancer

 So Hee Dho  ;  Soo Yong Kim  ;  Chaeuk Chung  ;  Eun Ha Cho  ;  So-Young Lee  ;  Ji Young Kim  ;  Lark Kyun Kim  ;  Sung-Won Min  ;  Jichul Lee  ;  Sung Hee Jung  ;  Jae Cheong Lim 
 SCIENTIFIC REPORTS, Vol.8(1) : 8960, 2018 
Journal Title
Issue Date
Decay-accelerating factor (CD55 or DAF) inhibits complement-dependent cytotoxicity. We determined that CD55 is overexpressed in 76.47% of human non-small cell lung cancer tissue specimens. We therefore developed a lutetium-177-labeled chimeric monoclonal antibody against CD55. CD55-specific single-chain variable fragment (scFv) was selected from a naive chicken scFv phage-display library, converted to IgG, and radiolabeled with lutetium-177 to generate a (177)Lu-anti-CD55 antibody. We then charaterized the biodistribution of this antibody in a mouse model of pleural metastatic lung cancer. The (177)Lu-anti-CD55 antibody was primarily retained in tumor tissue rather than normal tissue. Treatment of the mice with (177)Lu-anti-CD55 reduced the growth of lung tumors and improved median survival in vivo by two-fold compared to controls. Finally, (177)Lu-anti-CD55 also enhanced the antitumor activity of cisplatin both in vitro and in vivo. These data suggest (177)Lu-anti-CD55 antibody is a promising theranostic agent for pleural metastatic lung cancer.
Files in This Item:
T201801951.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > BioMedical Science Institute (의생명과학부) > 1. Journal Papers
Yonsei Authors
Kim, Lark Kyun(김락균) ORCID logo https://orcid.org/0000-0001-5983-4470
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.